Reaction

Human Polyomavirus Infection reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 513 reports · 34 co-occurring drugs

As of the last recalculation, Human Polyomavirus Infection appears in 513 FAERS reports alongside 34 co-occurring drug terms. The strongest observed disproportionality signal is TACROLIMUS OINTMENT 0.1% (PRR 209.3).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Tacrolimus Ointment 0.1%	286	209.3	209.8
Tacrolimus Extended-Release Capsules	286	208.8	209.2
Busulfan	63	185.1	185.8
Tacrolimus	295	178.5	178.8
Thiotepa	30	135.3	135.7
Mycophenolate Mofetil	227	120.8	121.0
Mycophenolate Mofetil Hydrochloride	227	120.6	120.8
Everolimus Tablets	43	113.5	113.8
Polatuzumab Vedotin	21	91.0	91.2
Fludarabine Phosphate	73	87.7	87.8
Bendamustine Hcl	29	80.4	80.5
Sirolimus	25	79.1	79.2
Alemtuzumab	33	73.9	74.0
Valganciclovir Hydrochloride Powder,	18	62.0	62.1
Ganciclovir	14	57.0	57.1
Mycophenolic Acid	41	56.4	56.5
Ganciclovir Sodium	14	55.2	55.2
Micafungin Sodium	10	48.8	48.8
Basiliximab	13	46.0	46.0
Mycophenilic Acid	22	45.0	45.0
Voriconazole Injection	23	44.9	45.0
Valganciclovir	19	42.4	42.5
Valganciclovir Hydrochloride	19	42.4	42.5
Cyclophosphamide Injection, Solution	132	40.4	40.4
Cyclophosphamide	132	40.4	40.4
Cyclophosphamide For Injection	132	40.4	40.4
Melphalan	21	39.0	39.0
Voriconazole	27	38.0	38.0
Everolimus	43	37.3	37.4
Melphalan Hydrochloride	21	35.4	35.4
Anti-Thymocyte Globulin (Rabbit)	6	30.5	30.5
Bendamustine Hydrochloride	8	27.5	27.5
Posaconazole Delayed-Release	7	26.2	26.2
Daratumumab	15	15.7	15.7

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.